Work

Nivolumab Plus Relatlimab: First Approval

Year: 2022
Type: article
Source: Drugs
Author: Julia Paik
Language: French
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W4280599663
FWCI: 17.78
Cites: 12
Cited by: 186
Related to: 10